Search results for: 'image plan'

With an inclination toward patient-centric care delivery, the pharma industry follows a robust, step-by-step approach to market commercialization, with a clear understanding of the market stakeholders, segments, and post-launch forecasts to create seamless go-to-market strategies, develop a positive image, and instill confidence among healthcare pr...

With the growing preference for a patient-centric care delivery approach, the pharma industry follows a robust step-by-step approach towards market commercialization, with a clear understanding of the market stakeholders, segments, as well as post-launch forecasts to create seamless go-to-market strategies. To cater to the ever-evolving market land...

20 Aug 2024  |  Global  |  Technology Research

Technological Advances in Regenerative Medicine

Disruptive Technology and a Competitive Landscape Drive Growth in Stem Cell Therapy Research

Infographics

×

Regenerative medicine has evolved significantly and today includes several commercialized stem cell therapies. Researchers have made notable technological developments in stem cell therapies to overcome challenges related to large-scale manufacturing and cell quality. Stem cell research is more focused on induced pluripotent stem cells than on mese...

The rising global prevalence of neurodegenerative diseases (NDDs) is driving the shift from symptom-to-disease-modifying therapeutics that target unique pathological mechanisms, such as protein misfolding, neuroinflammation, and synaptic dysfunction, and customizing treatment based on unique genetic profiles, disease subtypes, and distinct biomarke...

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...